BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)
Status:
Completed
Trial end date:
2017-07-10
Target enrollment:
Participant gender:
Summary
Adult patients with chronic lymphocytic leukaemia who experience a relapse after at least two
prior treatment regimens may be enrolled in this trial. The trial will examine whether
monotherapy with BI 836826 is safe and tolerable at escalating dose levels.